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 Metabolic pathways for caffeine
(in mice - human overlaps underlined)
Caffeine is broken down in humans by several enzymes from the Cytochrome 
P450 (CYP) superclass of enzymes. These CYP enzymes are important in 
activating or eliminating many medications. The evaluation of caffeine 
metabolites in a patient has been proposed as a means of estimating the activity 
of some CYP enzymes, contributing to genetics-based personalized medicine. 
The frequency and distribution of polymorphisms in inbred strains of mice 
often mirrors the variety in genotypes found in human populations. 
This project hopes to determine whether four inbred strains have enough inter-
strain differences in both their metabolite phenotypes and expression of mouse 
CYP enzymes to support additional investigations.
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3. Methods
Overall process of project
Cytochrome P450 Enzymes
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• The DBA/2J strain may be a slow metabolizer by a significant amount. 
Other time points besides 30 minutes after dose may be able to confirm.
• qPCR data is still pending as of 8/4/2011.
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Several polymorphic CYP proteins outside of this 
study's scope have already been characterized in 
Caucasian populations with enough detail to warrant 
clinical dosing decisions based on CYP genotype1. The 
current understanding of CYP1A2 and CYP3A4/5 
genetics still needs more development before being 
applied to personalized medicine. Caffeine metabolism 
(specifically Paraxanthine/Caffeine ratios) serves as a 
clinically recognized indicator of CYP1A2 activity2.
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C-8-hydroxylation   CYP1A2 > CYP2B6 > CYP2E1 > CYP2D6 > CYP2C18 > CYP3A4
  CYP1A2 > CYP2D6 > CYP2C9 > CYP2E1 > CYP2A6 > CYP3A57-N-demethylation
  CYP1A2 > CYP3A4 > CYP2C9 > CYP2C8 > CYP2D6 > CYP2E13-N-demethylation
  CYP1A2 > CYP2D6 > CYP2C8 > CYP2C19 > CYP3A51-N-demethylation
Preference of human CYP Enzymes for caffeine catalysisPathway
(Source: Kot and Daniel. 2008)
Relative CYP strengths metabolizing caffeine in human liver microsomes
CYP1A2 is the primary enzyme responsible for caffeine metabolism in mice and 
humans - eliminating 87% of caffeine at normal concentrations in mice3. 
CYP2A6, CYP2E1, and CYP3A4 have been shown to play a role in caffeine 
metabolism in humans, and in wild-type mice the orthologous  genes are 
expressed in similar patterns4 but may not have the exact same roles in caffeine 
metabolism.  Rat caffeine metabolism has significantly different characteristics.
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Caffeine
High Performance Liquid Chromatography (HPLC)
• Blood sample was centrifuged to isolate plasma
• Proteins were precipitated using 100% Methanol  (200 !l of MeOH + 100 !l plasma)
• Protein-free precipitate was evaporated and reconstituted in 50!l 10% Methanol
• 40!l of reconstituted sample was injected into HPLC device. 
Non-polar compounds are attracted to the analytical column and take longer to reach the 
detector.  More polar compounds (metabolites) are forced off the column by increasing 
concentrations of the organic buffer.
* Solvent A: 99.99% HPLC grade H20 and 0.01% Acetic Acid (pH 4) 
* Solvent B: 90% Methanol, 10% Acetonitrile and 0.01% Acetic Acid (pH4)
Reverse Transcriptase Polymerase Chain Reaction (rtPCR) and
Quantitative Real Time Polymerase Chain Reaction (qPCR)
• Tissue Samples were preserved after collection in 3ml of RNALater®  and stored at -4°C
• ~30mg of tissue was homogenized in TRIzol and purified to total mRNA using 
QIAGEN RNeasy columns and reagents. Yield ranged from 1.2-4.0 !g mRNA/!l water.
• Total cDNA for each sample was made using Invitrogen's SuperScript™ First-Strand 
Synthesis System. 
• cDNA was amplified using a standard PCR protocol and the primers listed above.
• qPCR was conducted with the same cDNA primers were ordered from Applied 
Biosystems for use with a TaqMan® qPCR device and reagents.
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Sample gel electrophoresis of rtPCR products
Protocol for HPLC Samples
This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344 LLNL-POST-491655
3455' AACAGAAAGCCATAGCGCAGGG 3'5' GCTTCGAATGATGCTGGGAAGCT 3'Cyp2a5
269
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Product 
Length (bp)
5'TAGCCCGTATCTGGTGCTGAAGGA3'
5' AAACCTCCGCACGTCCTTCCAT 3'
5'TGTGACAGCAAGGAGAGGCGTTT3'
Reverse Primer (-)
5' TCCTCTGCACGTTAGGCCATGT 3'Cyp1a2
5'AAGACCGGGAGAGAACAGCACAAC3'
Gene
NAT2
5' ACCGTTGCCTTGCTTGTCTGGA 3'Cyp2e1
5'ACAAACAAGCAGGGATGGACCTGG3'
Forward Primer (+)
Cyp3a11
5' AGAGGTTGGCCACTTCGAACCA 3'
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C5
7B
L/
6J
BA
LB
/cJ
CB
A/
J
D
BA
/2J
C5
7B
L/
6J
BA
LB
/cJ
CB
A/
J
D
BA
/2J
C5
7B
L/
6J
BA
LB
/cJ
CB
A/
J
D
BA
/2J
C5
7B
L/
6J
BA
LB
/cJ
CB
A/
J
D
BA
/2J
C5
7B
L/
6J
BA
LB
/cJ
CB
A/
J
D
BA
/2J
Cyp2e1 - 366bp
NAT2 -223bp
Cyp3a11- 269bp Cyp2a5- 345bp
• While the theobromine levels appear reliable within each strain, the 
amounts detected are close to the limits of the device's detection range and 
should not be weighted too heavily in the consideration of the data.
Adapted from: http://www.genome.jp/kegg-bin/show_pathway?
• The BALB/cJ strain metabolized caffeine into theophylline by a significantly 
larger amount than other strains. BALB/cJ's paraxanthine level was not 
significantly greater than C57BL/6J or CBA/J, but significant differences may 
arise through additional sampling or at other time points.
• rtPCR (not a quantitative method) did not 
reveal any obvious inter-strain differences in 
gene expression (no strains are null for a gene).
* See "sample gel electrophoresis" figure.
*While retention times were similar, not all sample peaks 
were recognized as theobromine by the HPLC software.
This work represents the first steps of a larger investigation, and the BALB/cJ and 
DBA/2J strains have emerged as candidate model organisms for human CYP 
polymorphisms detectable by caffeine metabolite levels. In the next stage, eleven 
additional mouse strains will be examined for mRNA expression levels.
While paraxanthine was expected to be the primary metabolite, after thirty minutes 
theophylline was detected at similar levels. Data will need to be collected two hours 
after injection for a closer comparison to published paraxanthine/caffeine ratios. A 
1,3,7-Trimethyluric acid standard will be prepared and checked against existing 
chromatogram data. A small peak near theobromine is a likely possibility.
Identified candidate mouse strains will have their mRNA sequences determined to 
more carefully characterize polymorphisms that could influence catalytic activity.
